For the quarter ending 2026-03-31, CNTA had $1,132K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -79,241 | -66,163 | -54,891 | -50,343 |
| Share-based compensation expense | 10,565 | 7,936 | 7,194 | 7,949 |
| Loss on extinguishment of debt | - | 0 | - | - |
| Depreciation and amortization | 239 | 241 | 237 | 226 |
| Amortization of discount of marketable securities | -811 | -447 | 114 | 53 |
| Change in fair value of financial instruments | - | 0 | - | 0 |
| Amortization of debt issuance costs and exit fee of long-term debt | 345 | 279 | 271 | 293 |
| Change in deferred taxes | 828 | 233 | 255 | 1,026 |
| Tax incentive receivable | 3,614 | 3,722 | 9,983 | -10,731 |
| Prepaid expenses and other assets | -3,535 | 5,942 | 3,935 | -4,701 |
| Operating leases, net | 53 | 62 | 63 | 63 |
| Accounts payable | 3,263 | -1,312 | 3,280 | 177 |
| Accrued expenses and other liabilities | -9,015 | 12,142 | -689 | 2,881 |
| Other, net | 7 | -8 | -103 | - |
| Net cash used in operating activities | -72,224 | -55,807 | -58,312 | -22,452 |
| Purchases of investments in marketable securities | 75,539 | 313,712 | 45,512 | 83,061 |
| Proceeds from maturities of investments in marketable securities | 118,246 | 95,589 | 107,691 | 43,233 |
| Purchase of property and equipment | - | 11 | 234 | 126 |
| Net cash (used in) provided by investing activities | 42,707 | -218,134 | 61,945 | -39,954 |
| Proceeds from issuance of shares, net of issuance costs-Underwriter Offering | - | 269,249 | 0 | 0 |
| Proceeds from issuance of shares, net of issuance costs-At The Market Program | - | 0 | 0 | 0 |
| Repayment of debt | - | 0 | - | - |
| Proceeds from issuance of shares under atm program, net of issuance costs | 0 | - | - | - |
| Proceeds from issuance of debt, net of issuance costs | - | 0 | - | - |
| Proceeds from option exercises | 34,121 | 14,332 | 3,562 | 1,705 |
| Payment of employee withholding taxes related to withheld shares for stock based compensation plans | 3,654 | 176 | 125 | 4,490 |
| Other, net | 0 | -5 | 0 | 4,390 |
| Net cash provided by financing activities | 30,467 | 283,400 | 3,437 | 1,605 |
| Effect of exchange rate on cash and cash equivalents | 182 | 1,683 | -501 | -113 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 1,132 | 11,142 | 6,569 | -60,914 |
| Cash, cash equivalents, and restricted cash at beginning of period | 61,953 | 50,811 | 44,242 | 105,156 |
| Cash, cash equivalents, and restricted cash at end of period | 63,085 | 61,953 | 50,811 | 44,242 |
Centessa Pharmaceuticals plc (CNTA)
Centessa Pharmaceuticals plc (CNTA)